Alpha-synuclein and the Parkinson's disease drug pipeline-Reference-Cited by-同舟云学术

Alpha-synuclein and the Parkinson's disease drug pipeline

Published:2023-06 Issue: Volume:111 Page:105432
ISSN:1353-8020
Container-title:Parkinsonism & Related Disorders
language:en
Short-container-title:Parkinsonism & Related Disorders

Author:

Espay Alberto J.^ORCID,McFarthing Kevin

Publisher

Elsevier BV

Subject

Neurology (clinical),Geriatrics and Gerontology,Neurology

Reference18 articles.

1. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia;Parkkinen;Ann. Neurol.,2005

2. A critical evaluation of the Braak staging scheme for Parkinson's disease;Burke;Ann. Neurol.,2008

3. Disentangling the relationship between lewy bodies and nigral neuronal loss in Parkinson's disease;Parkkinen;J. Parkinsons Dis.,2011

4. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease;Kang;JAMA Neurol.,2013

5. Low soluble amyloid-β 42 is associated with smaller brain volume in Parkinson's disease;Espay;Parkinsonism Relat. Disorders,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating through the complexities of synucleinopathies: Insights into pathogenesis, heterogeneity, and future perspectives;Neuron;2024-06

2. Loss of monomeric alpha-synuclein (synucleinopenia) and the origin of Parkinson's disease;Parkinsonism & Related Disorders;2024-05

3. Tackling vascular risk factors as a possible disease modifying intervention in Parkinson’s disease;npj Parkinson's Disease;2024-03-02